4142:TPE
Adimmune Corp
17,90Â NT$
arrow_upward
+0,56%(+0,10) 1 p
21. okt, 13:30:30 GMT +8 · TWD
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse 4142 põhistatistika genereerimine…
Ava
18,00Â NT$
Kõrge
18,05Â NT$
Madal
17,85Â NT$
Turu kapit.
7,69Â mld
Keskm. maht
1,06Â mln
Maht
367,00Â tuh
52 näd kõrgeim
22,50Â NT$
52 näd madalaim
16,40Â NT$
Aktsiatulu
−0,34 NT$
Käibivad aktsiad
235,29Â mln
Töötajate arv
564
Ava
18,00Â NT$
Kõrge
18,05Â NT$
Madal
17,85Â NT$
Turu kapit.
7,69Â mld
Keskm. maht
1,06Â mln
Maht
367,00Â tuh
52 näd kõrgeim
22,50Â NT$
52 näd madalaim
16,40Â NT$
Aktsiatulu
−0,34 NT$
Käibivad aktsiad
235,29Â mln
Töötajate arv
564
Uudised
Veebiallikatest ja uudistepartneritelt
Yahoo
·
31 minuti eest
Nasdaq leads Wall Street gains as SpaceX, Super Micro aid AI sentiment
24/7 Wall St.
·
15 minuti eest
JEPQ Held Up Better in All 9 Down Months and Trailed in 11 of 15 Up Months. The Two-Year Score: 39.97% vs. 53.25%
PR Newswire
·
17 minuti eest
Direct Digital Holdings Announces Intention to Voluntarily Delist from Nasdaq and Deregister Its Class A Common Stock with the SEC
Investor's Business Daily
·
2 tunni eest
Dow Jones Futures: Meta, Tesla Are Earnings Movers Late After SpaceX, Super Micro Lead Bullish Nasdaq Move
Profiil
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Teave üksuse Adimmune Corp kohta